Clinical Trials Logo

Solid Tumours clinical trials

View clinical trials related to Solid Tumours.

Filter by:

NCT ID: NCT00732420 Completed - Solid Tumours Clinical Trials

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Start date: September 24, 2008
Phase: Phase 1
Study type: Interventional

To determined what dose of topotecan can be safely given with daily pazopanib.

NCT ID: NCT00695448 Terminated - Solid Tumours Clinical Trials

Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma

Start date: June 24, 2008
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center Phase I study conducted to define the recommended Phase 2 dose, toxicity profile, pharmacokinetics and biologically active dose range of GSK1059615.

NCT ID: NCT00687622 Completed - Solid Tumours Clinical Trials

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

Start date: July 28, 2008
Phase: Phase 1
Study type: Interventional

MEK111054 is a first-time-in-human, open-label study to determine recommended dose and regimen for the orally administered GSK1120212. The study consists of three parts. Part 1 will identify the maximum tolerated dose. Part 2 will explore the safety, tolerability, and effectiveness of GSK1120212. Part 3 will determine a range of effective doses.

NCT ID: NCT00497679 Terminated - Solid Tumours Clinical Trials

AZD1152 in Patients With Advanced Solid Malignancies-Study 3

Start date: August 2006
Phase: Phase 1
Study type: Interventional

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 7-day infusion every week and every 2 weeks in patients with advanced solid malignancies.

NCT ID: NCT00483860 Completed - Solid Tumours Clinical Trials

A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function

Start date: June 20, 2007
Phase: Phase 1
Study type: Interventional

To determine the effect of renal impairment and prior platinum-based chemotherapy on the safety and blood levels of topotecan administered orally

NCT ID: NCT00136578 Completed - Solid Tumours Clinical Trials

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Start date: October 20, 2004
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the dose regimen of Ispinesib in combination with carboplatin in patients with solid tumors. Ispinesib is dosed by 1-hour intravenous infusion and carboplatin is dosed by 30 minute intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with Ispinesib. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.